Safe-Testing Algorithm for Individual-Donation Nucleic Acid Testing: 10 Years of Experience in a Low-Prevalence Country
A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) is essential for the safety of blood components. Since more than 2 decades, NAT screening of blood donations has become standard in develop...
Gespeichert in:
| Veröffentlicht in: | Transfusion medicine and hemotherapy Jg. 46; H. 2; S. 104 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
01.04.2019
|
| Schlagworte: | |
| ISSN: | 1660-3796 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) is essential for the safety of blood components. Since more than 2 decades, NAT screening of blood donations has become standard in developed countries that have implemented the individual-donation (ID-NAT) and mini-pool NAT (MP-NAT) approaches. With this powerful technique, confirmation of initial reactive (IR) NAT samples becomes a challenge. Different algorithms are currently in use to eliminate false reactive results. To show that the algorithm implemented in 2007, that uses repeat testing of IR samples in duplicate runs, is a safe strategy, especially in low endemic countries, data from a 10-year experience of ID-NAT were extensively analyzed when follow-up data were available.
From July 2007 to December 2014, the Procleix Ultrio assay on a Procleix Tigris system, and from January 2015 to December 2017, the cobas MPX on a cobas 8800 platform, were used for ID-NAT screening. All IR samples were subjected to repeat testing in duplicate independent runs. Only when both tests remained negative were the products released. Donor data from the last 10 years were investigated retrospectively, looking for the reoccurrence of a reactive result in a follow-up sample. Only those donors with at least an x + 1 donation result were included for the confirmation of a false reactive result.
From the 1,830,657 donations tested, 2,450 samples were IR (0.13%); only 228 were repeat reactive ([RR], 18 HIV, 61 HCV, and 149 HBV samples), and 2,222 were non-RR (0.12%). Follow-up data were available from 1,267 donors (57%) for further analysis. All except one of these donors were ID-NAT-negative in all follow-up samples. The one exception was from a donor who acquired a fresh HBV infection 10 years after the IR donation (in the x + 28 donation) and subsequently seroconverted. Subsequent serological tests from all succeeding donations (x + 1, x + 2, etc.) were negative in all the other cases, proving that no seroconversion took place after the IR ID-NAT result.
The algorithm to deal with IR ID-NAT donations using duplicate repeat testing is very safe and cost-effective in low-prevalence countries. There is no unnecessary destruction of blood products, no counseling of false reactive donors, and also no need to add further complexity to the screening algorithm. |
|---|---|
| AbstractList | A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) is essential for the safety of blood components. Since more than 2 decades, NAT screening of blood donations has become standard in developed countries that have implemented the individual-donation (ID-NAT) and mini-pool NAT (MP-NAT) approaches. With this powerful technique, confirmation of initial reactive (IR) NAT samples becomes a challenge. Different algorithms are currently in use to eliminate false reactive results. To show that the algorithm implemented in 2007, that uses repeat testing of IR samples in duplicate runs, is a safe strategy, especially in low endemic countries, data from a 10-year experience of ID-NAT were extensively analyzed when follow-up data were available.INTRODUCTIONA highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) is essential for the safety of blood components. Since more than 2 decades, NAT screening of blood donations has become standard in developed countries that have implemented the individual-donation (ID-NAT) and mini-pool NAT (MP-NAT) approaches. With this powerful technique, confirmation of initial reactive (IR) NAT samples becomes a challenge. Different algorithms are currently in use to eliminate false reactive results. To show that the algorithm implemented in 2007, that uses repeat testing of IR samples in duplicate runs, is a safe strategy, especially in low endemic countries, data from a 10-year experience of ID-NAT were extensively analyzed when follow-up data were available.From July 2007 to December 2014, the Procleix Ultrio assay on a Procleix Tigris system, and from January 2015 to December 2017, the cobas MPX on a cobas 8800 platform, were used for ID-NAT screening. All IR samples were subjected to repeat testing in duplicate independent runs. Only when both tests remained negative were the products released. Donor data from the last 10 years were investigated retrospectively, looking for the reoccurrence of a reactive result in a follow-up sample. Only those donors with at least an x + 1 donation result were included for the confirmation of a false reactive result.METHODSFrom July 2007 to December 2014, the Procleix Ultrio assay on a Procleix Tigris system, and from January 2015 to December 2017, the cobas MPX on a cobas 8800 platform, were used for ID-NAT screening. All IR samples were subjected to repeat testing in duplicate independent runs. Only when both tests remained negative were the products released. Donor data from the last 10 years were investigated retrospectively, looking for the reoccurrence of a reactive result in a follow-up sample. Only those donors with at least an x + 1 donation result were included for the confirmation of a false reactive result.From the 1,830,657 donations tested, 2,450 samples were IR (0.13%); only 228 were repeat reactive ([RR], 18 HIV, 61 HCV, and 149 HBV samples), and 2,222 were non-RR (0.12%). Follow-up data were available from 1,267 donors (57%) for further analysis. All except one of these donors were ID-NAT-negative in all follow-up samples. The one exception was from a donor who acquired a fresh HBV infection 10 years after the IR donation (in the x + 28 donation) and subsequently seroconverted. Subsequent serological tests from all succeeding donations (x + 1, x + 2, etc.) were negative in all the other cases, proving that no seroconversion took place after the IR ID-NAT result.RESULTSFrom the 1,830,657 donations tested, 2,450 samples were IR (0.13%); only 228 were repeat reactive ([RR], 18 HIV, 61 HCV, and 149 HBV samples), and 2,222 were non-RR (0.12%). Follow-up data were available from 1,267 donors (57%) for further analysis. All except one of these donors were ID-NAT-negative in all follow-up samples. The one exception was from a donor who acquired a fresh HBV infection 10 years after the IR donation (in the x + 28 donation) and subsequently seroconverted. Subsequent serological tests from all succeeding donations (x + 1, x + 2, etc.) were negative in all the other cases, proving that no seroconversion took place after the IR ID-NAT result.The algorithm to deal with IR ID-NAT donations using duplicate repeat testing is very safe and cost-effective in low-prevalence countries. There is no unnecessary destruction of blood products, no counseling of false reactive donors, and also no need to add further complexity to the screening algorithm.CONCLUSIONSThe algorithm to deal with IR ID-NAT donations using duplicate repeat testing is very safe and cost-effective in low-prevalence countries. There is no unnecessary destruction of blood products, no counseling of false reactive donors, and also no need to add further complexity to the screening algorithm. A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B (HBV) is essential for the safety of blood components. Since more than 2 decades, NAT screening of blood donations has become standard in developed countries that have implemented the individual-donation (ID-NAT) and mini-pool NAT (MP-NAT) approaches. With this powerful technique, confirmation of initial reactive (IR) NAT samples becomes a challenge. Different algorithms are currently in use to eliminate false reactive results. To show that the algorithm implemented in 2007, that uses repeat testing of IR samples in duplicate runs, is a safe strategy, especially in low endemic countries, data from a 10-year experience of ID-NAT were extensively analyzed when follow-up data were available. From July 2007 to December 2014, the Procleix Ultrio assay on a Procleix Tigris system, and from January 2015 to December 2017, the cobas MPX on a cobas 8800 platform, were used for ID-NAT screening. All IR samples were subjected to repeat testing in duplicate independent runs. Only when both tests remained negative were the products released. Donor data from the last 10 years were investigated retrospectively, looking for the reoccurrence of a reactive result in a follow-up sample. Only those donors with at least an x + 1 donation result were included for the confirmation of a false reactive result. From the 1,830,657 donations tested, 2,450 samples were IR (0.13%); only 228 were repeat reactive ([RR], 18 HIV, 61 HCV, and 149 HBV samples), and 2,222 were non-RR (0.12%). Follow-up data were available from 1,267 donors (57%) for further analysis. All except one of these donors were ID-NAT-negative in all follow-up samples. The one exception was from a donor who acquired a fresh HBV infection 10 years after the IR donation (in the x + 28 donation) and subsequently seroconverted. Subsequent serological tests from all succeeding donations (x + 1, x + 2, etc.) were negative in all the other cases, proving that no seroconversion took place after the IR ID-NAT result. The algorithm to deal with IR ID-NAT donations using duplicate repeat testing is very safe and cost-effective in low-prevalence countries. There is no unnecessary destruction of blood products, no counseling of false reactive donors, and also no need to add further complexity to the screening algorithm. |
| Author | Gowland, Peter Niederhauser, Christoph Stolz, Martin Tinguely, Caroline |
| Author_xml | – sequence: 1 givenname: Martin surname: Stolz fullname: Stolz, Martin organization: Interregional Blood Transfusion SRC, Laboratory Diagnostics, Bern, Switzerland – sequence: 2 givenname: Peter surname: Gowland fullname: Gowland, Peter organization: Interregional Blood Transfusion SRC, Laboratory Diagnostics, Bern, Switzerland – sequence: 3 givenname: Caroline surname: Tinguely fullname: Tinguely, Caroline organization: Interregional Blood Transfusion SRC, Laboratory Diagnostics, Bern, Switzerland – sequence: 4 givenname: Christoph surname: Niederhauser fullname: Niederhauser, Christoph organization: Faculté de biologie et de médecine, Universite de Lausanne, Lausanne, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31191196$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kEtPwzAQhH0oog848AeQj1wCfiROzK0qBSpFgEQ5cIocP4pRYhc7aem_J4IijXak0ber1UzByHmnAbjA6BrjjN8ghFLOMWMjMBkmSmjO2RhMY_xEiKQFJadgTDHmg9gE7F-F0clax866DZw3Gx9s99FC4wNcOWV3VvWiSe68E531Dj71stFWwrm0Ch7XbiFG8F2LEKE3cPm91cFqJzW0DgpY-n3yEvRONL_ZwveuC4czcGJEE_X50Wfg7X65Xjwm5fPDajEvE5mStEsUVURyzHNSSKMoV7VheY6MyQoiFeGiRsLUheSFyevMpFgTyZjMcC7rWjBCZuDq7-42-K9--LdqbZS6aYTTvo8VoelQGM1IPqCXR7SvW62qbbCtCIfqvyzyA5Lfavo |
| CitedBy_id | crossref_primary_10_1016_j_chieco_2025_102391 crossref_primary_10_1159_000513179 crossref_primary_10_1159_000502552 crossref_primary_10_1159_000525480 crossref_primary_10_3389_fimmu_2022_754383 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1159/000499166 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 31191196 |
| Genre | Journal Article |
| GroupedDBID | --- 0~5 0~B 123 30W 328 3O. 4.4 53G 8UI AAYIC ABBTS ABJNI ABPAZ ABWCG ACGFO ACGFS ACPSR ADBBV AENEX AEYAO AFJJK AHFRZ ALDHI ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC CAG COF CS3 CYUIP DU5 E0A EBS EJD FB. GROUPED_DOAJ GX1 HYE HZ~ IAO IHR INH ITC IY7 KUZGX M-- N9A NPM O1H O9- OK1 RIG RKO RPM RXVBD UJ6 7X8 |
| ID | FETCH-LOGICAL-c424t-d3d2c919728cfd39dbf6770ff582cd29ab0afb8c98f7b5f41e2c66c517cbba622 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000464389300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1660-3796 |
| IngestDate | Fri Jul 11 12:24:02 EDT 2025 Wed Feb 19 02:27:04 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Individual donations Blood-borne viruses Mini-pools Nucleic acid test |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c424t-d3d2c919728cfd39dbf6770ff582cd29ab0afb8c98f7b5f41e2c66c517cbba622 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.karger.com/Article/Pdf/499166 |
| PMID | 31191196 |
| PQID | 2340043527 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2340043527 pubmed_primary_31191196 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-01 |
| PublicationDateYYYYMMDD | 2019-04-01 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Transfusion medicine and hemotherapy |
| PublicationTitleAlternate | Transfus Med Hemother |
| PublicationYear | 2019 |
| SSID | ssj0024832 |
| Score | 2.1829827 |
| Snippet | A highly sensitive and specific nucleic acid test (NAT) for the blood-borne viruses human immunodeficiency virus (HIV), hepatitis C (HCV), and hepatitis B... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 104 |
| Title | Safe-Testing Algorithm for Individual-Donation Nucleic Acid Testing: 10 Years of Experience in a Low-Prevalence Country |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31191196 https://www.proquest.com/docview/2340043527 |
| Volume | 46 |
| WOSCitedRecordID | wos000464389300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbwGN9lHsl6kiEXBloIV6qlkJ0kt6G5tq8V_b7Kb2osHwcuyl4QlM5l8O5P5PoQuEqql_f03ROhIkUhqQ1IWhARcuIRYCMpVKTbB223R66Udn3Cb-GuV85hYBmpVgMuRX7LQeZuFC_x69E6capSrrnoJjWVUCy2UcV7Ne2LBtSdKgTKaJDbW8DTxzEL2BL-ssD715Ii_IsvyhGlu_vfbttCGx5a4UTnDNlrS-Q5aa_nq-S6aPUqjSdfxauQD3Hgd2DmmL2_Y4lZ8_9OYRVy62JkLtx3X8RBwA4YK-2FXmAb42W6PCS4MXhAl42GOJX4oZsSRQsmylQm7hvfp-GsPPTVvuzd3xAsvEIhYNCUqVAxSJ0gmwKgwVZlJOA-MiQUDxVKZBdJkAlJheBabiGoGibUs5ZBlMmFsH63kRa4PETYQG5oFQsmYRSq0LwEHoamxQBXAQB2dz5e0bx3bVStkrouPSX-xqHV0UNmlP6oYOPqho6WzsePoD6OP0boFOWl12-YE1Yzd1voUrcLndDgZn5UeY5_tTusbthzMJA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safe-Testing+Algorithm+for+Individual-Donation+Nucleic+Acid+Testing%3A+10+Years+of+Experience+in+a+Low-Prevalence+Country&rft.jtitle=Transfusion+medicine+and+hemotherapy&rft.au=Stolz%2C+Martin&rft.au=Gowland%2C+Peter&rft.au=Tinguely%2C+Caroline&rft.au=Niederhauser%2C+Christoph&rft.date=2019-04-01&rft.issn=1660-3796&rft.volume=46&rft.issue=2&rft.spage=104&rft_id=info:doi/10.1159%2F000499166&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-3796&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-3796&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-3796&client=summon |